Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.
Jolis L, Carabantes F, Pernas S, Cantos B, López A, Torres P, Funes C, Caballero D, Benedit P, Salar A; PRAXIS Study Group. Jolis L, et al. Eur J Cancer Care (Engl). 2013 Jul;22(4):513-21. doi: 10.1111/ecc.12057. Epub 2013 Jun 3. Eur J Cancer Care (Engl). 2013. PMID: 23730920
Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Ciruelos EM, Montaño A, Rodríguez CA, González-Flores E, Lluch A, Garrigós L, Quiroga V, Antón A, Malón D, Chacón JI, Velasco M, Gonzalez-Cortijo L, Jolis L, Echarri MJ, Muñoz M, Pascual T, Amigo Y, Casas M, Carrasco E, Casas A. Ciruelos EM, et al. Among authors: jolis l. Eur J Cancer Care (Engl). 2020 Jul;29(4):e13253. doi: 10.1111/ecc.13253. Epub 2020 Jun 23. Eur J Cancer Care (Engl). 2020. PMID: 32578279 Clinical Trial.
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Cañada JM, Cirauqui B, Rodríguez-Lescure Á, Alba E, Martínez-Jáñez N, Muñoz M, Antolín S, Álvarez I, Del Barco S, Sevillano E, Chacón JI, Antón A, Escudero MJ, Ruiz V, Carrasco E, Martín M; GEICAM. Ruíz-Borrego M, et al. Breast Cancer Res Treat. 2019 Aug;177(1):115-125. doi: 10.1007/s10549-019-05296-8. Epub 2019 May 31. Breast Cancer Res Treat. 2019. PMID: 31152327 Clinical Trial.
Mitomycin-C and vinblastine in advanced breast cancer.
Navarro M, Bellmunt J, Balañá C, Colomer R, Jolis L, del Campo JM. Navarro M, et al. Among authors: jolis l. Oncology. 1989;46(3):137-42. doi: 10.1159/000226702. Oncology. 1989. PMID: 2497417 Review.
Meningioma preceding breast cancer.
Colomer R, Jolis L, Hidalgo R, Rubio D. Colomer R, et al. Among authors: jolis l. Cancer Treat Rep. 1987 May;71(5):550-1. Cancer Treat Rep. 1987. PMID: 3032435 No abstract available.
17 results